• Skip to primary navigation
  • Skip to main content
  • 786-300-3183
  • [email protected]
  • Facebook
  • Twitter
Florida Society of Anesthesiologists

Florida Society of Anesthesiologists

  • About FSA
    • FSA Leadership
      • Distinguished Service Award Past Recipients
      • President Engagement Award Past Recipients
      • FSA Past Presidents
    • FSA Staff
    • Calendar of Events
    • Contact FSA
    • FSA Charter & Bylaws
    • FSA Speakers Bureau
  • Annual Meeting
    • Meeting Info
    • Call For Abstracts
    • Past Posters
      • 2022 FSA Podium and Poster Abstracts
      • 2021 FSA Posters
      • 2020 FSA Posters
      • 2019 FSA Posters
      • 2018 FSA Posters
    • Past Meetings
      • 2022 Annual Meeting Recap
      • 2019 Annual Meeting Recap
      • 2018 Annual Meeting Recap
  • FSAPAC
    • Donate to FSAPAC
    • FSAPAC Donors for 2022
  • Join/Renew Membership
    • FSA Membership Renewal
    • Join the Florida Society of Anesthesiologists (FSA)
  • Member Login
  • Member Section

2018 FSA Posters

P013: METHYLENE BLUE AS A POTENTIAL THERAPEUTIC AGENT IN DECOMPENSATED HEMORRHAGIC SHOCK
Cory D Jackson, Christopher Giordano, MD; University of Florida

Decompensated hemorrhagic shock is characterized by decreased cardiac output and arterial pressures, a compensatory release of endogenous vasopressors, and then delayed vascular decompensation where blood vessels fail to respond to endogenous vasopressors.  Methylene blue (MB) is a heterocyclic aromatic dye used in the treatment of methemoglobinemia and as a coloring dye for medical procedures that more recently has shown potential as a therapeutic agent in various clinical settings.  The role of this agent in decompensated hemorrhagic shock has not been well studied.  Here we present a case of a 77-year-old male presented with right retroperitoneal leiomyosarcoma involving the inferior vena cava, right renal vein, and right gonadal vein.  During surgery, the patient experienced uncontrolled bleeding from the inferior vena cava that despite aggressive resuscitation with crystalloids, blood components and vasopressors still resulted in decompensated hemorrhagic shock.  He was treated with two separate doses of methylene blue during different periods of hypotension that restored his mean arterial blood pressures to the mid 60’s.  While the utility of MB has been established in cases of cardiopulmonary bypass and liver transplant during periods referred to as vasoplegia, this case suggests that methylene blue is also a potential therapeutic agent to increase mean arterial blood pressures in decompensated hemorrhagic shock during all general surgery or trauma cases.

Copyright © 2023 Florida Society of Anesthesiologists ยท Managed by BSC Management, Inc.